linjc16/ctgov huggingface dataset:
Dynamic Electronic Filter for Arterial Waveform Distortion

Study Overview
=================
Brief Summary
-----------------
Invasive blood pressure (IBP) is the gold standard for arterial pressure (AP) monitoring in critically ill patients. Nevertheless, IBP may be affected by underdamping/resonance artifacts, that eventually lead to AP overestimation. In these cases, when a pulse contour method is applied, wrong hemodynamic data are also delivered by the monitor. In order to overtake this issue, MostCareUp (a PCM powered by Pressure Recording Analytical Method, PRAM), has been implemented with a dynamic electronic filter (EFMC) that automatically corrects the resonant AP waveform. In order to test the EFMC, the electronically corrected AP and the derived cardiac output were compared with respective raw data corrected with the Accudynamic, an adjustable damping device specifically manufactured for normalizing the pressure waveform (in our study: the reference method).

Official Title
-----------------
Arterial Pressure Waveform Distortion: a New Dynamic Electronic Filter for Automatic Correction of Underdamping/Resonance Artifact. A Prospective Study

Conditions
-----------------
Underdamping/Resonance Artifacts

Intervention / Treatment
-----------------
* Device: MostCareUp


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - ICU patients with invasive blood pressure (radial artery) affected by underdamping/resonance artifacts; Exclusion Criteria: - Arrhythmias

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: MostCareUp|Pressure transducers have been connected to the MostCareUp and the hemodynamic parameters compared as follows: no filter, electronic filter, no electronic filter plus Accudynamic (our reference system). Invasive pressure values have been then compared with the non-invasive ones.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The present study was aimed to test the MostCareUp electronic filter | To test the electronic filter comparing the electronically corrected arterial pressure and the derived cardiac output values with those corrected with the Accudynamic, a mechanical adjustable damping device commonly used in clinical practice. | 15 minutes |
Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery

Study Overview
=================
Brief Summary
-----------------
Study designed to evaluate the safety and efficacy of double staining with brilliant blue G 0.025% as an adjuvant to macular surgery. Patients undergoing surgery for macular hole or epiretinal membrane will be included. Safety will be evaluated by optic coherence tomography, pattern reversal electroretinogram and multifocal electroretinogram.

Official Title
-----------------
Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery

Conditions
-----------------
Macular Hole, Epiretinal Membrane

Intervention / Treatment
-----------------
* Drug: brilliant blue G


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient age 18 years of older Signing of informed consent Macular pathology requiring vitrectomy (epiretinal membrane, macular hole, vitreomacular traction syndrome) Exclusion Criteria: Diagnosis of glaucoma Known allergy to brilliant blue G

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Double staining with brilliant blue G during vitrectomy<br> | Drug: brilliant blue G<br>* Double staining with brilliant blue G 0.025% for macular surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thickness of ganglion cell layer - inner plexiform layer measured by optical coherence tomography | Average thickness of ganglion cell layer - inner plexiform layer measured by spectral domain optical coherence tomography | 6 months | 
| Amplitude of pattern reversal electroretinogram | Amplitude of pattern reversal electroretinogram (in microvolts) | 6 months | 
| Amplitude of b-wave of multifocal electroretinogram | Measurement of the amplitude of the b-wave of multifocal electroretinogram | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity | Visual acuity measured with an Early Treatment Diabetic Retinopathy Study chart | 6 months | 
| Complications | Presence of any ocular complication | 6 months |
Establishment of Vascular Permeability Model for Research Purpose by Human Umbilical Vascular Endothelial Cells

Study Overview
=================
Brief Summary
-----------------
HUVEC primary cells for researches about the relation between plasma leakage and infections.

Detailed Description
-----------------
This study is going to collect HUVEC primary cells to set up an in vitro model for researches about the relation between plasma leakage and infections.

Official Title
-----------------
Establishment of Vascular Permeability Model for Research Purpose by Human

Conditions
-----------------
Healthy People

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy pregnant women would like to join this study Exclusion Criteria: venereal disease
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Attention Training and Cognitive Therapy

Study Overview
=================
Brief Summary
-----------------
The present study aimed to investigate the efficacy and process of change that occurs in Attention Training in comparison to an established treatment for social phobia, Cognitive Therapy. A randomized trial was conducted in which participants were allocated to either six weeks of Attention Training or Cognitive Therapy. It was hypothesized that both treatments would be effective in reducing social phobia symptoms, but that Attention Training would work primarily by reducing levels of self focused attention, while Cognitive Therapy would work through changes to probability and threat appraisals.

Official Title
-----------------
Comparison of Attention Training and Cognitive Therapy in the Treatment of Social Phobia: a Randomized Controlled Trial

Conditions
-----------------
Social Phobia

Intervention / Treatment
-----------------
* Behavioral: Cognitive therapy
* Behavioral: attention training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age, be fluent in English have a primary concern of social anxiety that met DSM-IV criteria (APA, 2000) for social phobia. Both subtypes of social phobia, specific and generalized, were accepted into the study. Exclusion Criteria: the presence of comorbid condition(s) that were more severe than the presenting social phobia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Attention training<br> | Behavioral: attention training<br> <br> |
| Active Comparator: Cognitive therapy<br> | Behavioral: Cognitive therapy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery

Study Overview
=================
Brief Summary
-----------------
The whole blood Thrombelastograph (TEG®) Platelet Mapping™ assay measures clot strength, maximal amplitude (MA), reflecting maximal platelet function, and detects the reduction in platelet function, presented as percentage inhibition, by both aspirin and clopidogrel. A study reported that the TEG® can be used as routine monitoring of the variability in ADP receptor inhibition and of antiplatelet therapy. Therefore, using TEG Platelet Mapping assay, we could find out the perioperative clopidogrel responsiveness of the patients with ACS undergoing OPCAB. The purpose of this study is to determine whether the rate of the major adverse cardiac events (MACE, a combined endpoint of MI, revascularization and cardiac death) is higher in the patients with high degree of clopidogrel resistance, who are scheduled to undergo the OPCAB due to ACS.

Conditions
-----------------
Acute Coronary Syndrome (ACS)

Intervention / Treatment
-----------------
* Device: MACE after OPCAB
* Device: without MACE after OPCAB


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: the patients with ACS undergoing OPCAB the patients over 20 years of age the patient who have been taking [100 mg of Aspirin] and [75 mg of clopidogrel or 180 mg of ticagrelor] for more than one week and who continue within 3 to 5 days prior to surgery Exclusion Criteria: re-operation or emergency operation the patients with bleeding tendency of decreased liver function Left ventricular ejection fraction < 40% by echo preoperative hematocrit < 33% or platelet count < 100,000/mm3 or creatinine > 1.4 mg/dL abnormal preoperative prothrombin time or activated partial thromboplastin time preoperative use of other PO antiplatelet drugs or PO anticoagulants

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MACE group<br>the patients with MACE after OPCAB | Device: MACE after OPCAB<br> <br> |
| no MACE group<br>the patients without MACE after OPCAB | Device: without MACE after OPCAB<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of the major adverse cardiac events | major adverse cardiac events(MACE) includes the MI, revascularization and cardiac death. Rate of the MACE will be higher in the patients with high degree of clopidogrel resistance. | at 30 days after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
off-pump coronary artery bypass surgery, clopidogrel responsiveness, ischemic outcome
Interventional Study Collecting Quantitative and Qualitative Data About Patient With Non Treated Cancer

Study Overview
=================
Brief Summary
-----------------
This study aims to determine the impact of sociocognitive and emotional factors on the time of the initial consult

Detailed Description
-----------------
identify wich sociocognitive factors influence the delay to go to a doctor after the emergence of first symptoms

Official Title
-----------------
Determinants of the Consultation Delay in Cancers of the Upper Aero Digestive Tract

Conditions
-----------------
Upper Aerodigestive Tract Cancer

Intervention / Treatment
-----------------
* Behavioral: interview
* Behavioral: questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥ 18 years oral cavity cancer, oropharynx cancer, hypopharynx cancer, larynx cancer non treated cancer patient informed of his diagnosis speak fluent french patient covered by health insurance signed informed consent Inclusion Criteria for interviewed  patients : no speech troubles patient consents being recorded Exclusion Criteria: history of cancer psychological history patient under guardianship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: questionnaires<br>4 questionnaires to answer at baseline 45 minutes approx. | Behavioral: questionnaires<br>* questionnaires to answer at baseline 45 minutes<br>|
| Experimental: interview<br>semi directive interview 105 patients | Behavioral: interview<br>* 25 minutes of semi directive interview<br>Behavioral: questionnaires<br>* questionnaires to answer at baseline 45 minutes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time of first consultation | median time between date of symptoms appearance and date of first consultation | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| identify variables associated with time of consultation | medical data : medical history, symptoms, entry into care pathway sociodemographic and emotional indicators | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non treated cancer, oral cavity, oropharynx, hypopharynx, larynx, first consultation
A Post Marking Study to Evaluate the Safety of FluMist in Children

Study Overview
=================
Brief Summary
-----------------
To assess the safety of FluMist vaccination

Detailed Description
-----------------
To assess the safety of FluMist vaccination Rates of medically attended events in FluMist recipients, including serious adverse events (SAEs), anaphylaxis , urticaria, asthma, wheezing, pre-specified grouped diagnoses, and rare events potentially related to wild-type influenza, will be compared to rates in multiple non-randomized control groups. To assess the safety of annual FluMist re-vaccination [Rates of MAEs in the subset of children who receive FluMist in ≥2 consecutive years will be compared to rates in first-time vaccinees during the same season.] To assess the safety of FluMist vaccination in children previously vaccinated with trivalent inactivated influenza vaccine (TIV) [Rates of MAEs in the subset of children who received one or more prior TIV vaccinations will be compared to rates in children who did not receive prior TIV.]

Official Title
-----------------
A Post Marketing Evaluation of the Safety of FluMist in Children 24-59 Months of Age in a Managed Care Setting

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Biological: FLuMist
* Biological: TIV (Injection)
* Other: Unvaccinated Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy Age: born within the same calendar quarter as the reference FluMist vaccinee. Exclusion Criteria: Children who have evidence of medical conditions that put them at high risk for complications of influenza (e.g., chronic cardiovascular and pulmonary disease) will be excluded from this control group.

Ages Eligible for Study
-----------------
Minimum Age: 24 Months
Maximum Age: 59 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 2<br>TIV | Biological: TIV (Injection)<br>* One or two injections of TIV depending on previous status.<br>|
| 1<br>FluMist | Biological: FLuMist<br>* One or two vaccinations with FluMist depending on prior vaccination status.<br>|
| 3<br>Unvaccinated | Other: Unvaccinated Control<br>* no vaccine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess Medically Attended Events(MAEs)of anaphylaxis,urticaria, asthma,wheezing,pre-specified grouped diagnoses,and rare events related to wild-type influenza,MAEs-qualify as SAEs,in:emergency department,clinic,and hospital setting. |  | 1, 3, 21, or 42 days post dose; 6 months post dose; entire study period) |
Invasive Validation of Non-invasive Central Blood Pressure Measurements Using Oscillometric Pulse Wave Analysis

Study Overview
=================
Brief Summary
-----------------
There is growing evidence that central blood pressure is a better predictor of hypertensive end-organ damage and cardiovascular outcome than routine brachial readings. The investigators aimed to evaluate the accuracy of a novel device for the non-invasive determination of central blood pressure based on automated oscillometric radial pulse wave analysis.

Official Title
-----------------
Non-invasive Automated Central Blood Pressure Measurements Using Oscillometric Pulse Wave Analysis - Comparison With Invasive Reference Values

Conditions
-----------------
Arterial Hypertension, Coronary Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing routine coronary angiography Exclusion Criteria: inability to give informed consent hemodynamic instability

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| coronary angiography<br>patients undergoing routine coronary angiography, invasive and non-invasive determination of central blood pressure | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| agreement of systolic central blood pressure measurements |  | 15 minutes | 
| agreement of diastolic central blood pressure measurements |  | 15 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
central blood pressure, measurement, oscillometric radial pulse wave analysis
Diagnostic Accuracy of Optimized Diffusion-Weighted Imaging for Detecting Anterior Ischemic Optic Neuropathy

Study Overview
=================
Brief Summary
-----------------
The patient presents to the ophthalmological emergencies and / or to the internal medicine department. NOIA clinical discovery Patient referred in radiology for brain and visual MRI. The two sequences added by the research (8 minutes) will be added to that of the treatment.

Official Title
-----------------
Diagnostic Accuracy of Optimized Diffusion-Weighted Imaging for Detecting Anterior Ischemic Optic Neuropathy

Conditions
-----------------
Neuro-Ophthalmology

Intervention / Treatment
-----------------
* Other: MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient over 18 years old Patient with suspected NOIA, evoked after clinical examination by a specialized ophthalmologist For which a brain and visual MRI is planned Express consent to participate in the study Affiliate or beneficiary of a Social Security scheme Exclusion Criteria: Contraindication to MRI (electrical device, metallic foreign body, claustrophobia) Patient benefiting from a legal protection measure Pregnant or breastfeeding woman

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: MRI|Diffusion sequence (8 minutes long) added to the initial MRI|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study the sensitivity of the High resolution Diffusion sequence in the detection of NOIA, evaluated by a DWI hypersignal and an ADC hyposignal of the optic nerve |  | basline |
Oral Immunotherapy for Peanut and Mammalian Meat Allergies

Study Overview
=================
Brief Summary
-----------------
Pilot study to assess the effect of oral immunotherapy on specific Immunoglobulin E (IgE) levels and antigen consumption in two distinct food allergies.

Detailed Description
-----------------
In subjects with mammalian meat allergy, the effect of daily oral cow's milk on immune parameters and desensitization will be assessed. Similarly, in subjects with a peanut allergy the effects of low dose peanut flour will be assessed and comparisons between two distinct food allergies.

Official Title
-----------------
Oral Immunotherapy for Peanut and Mammalian Meat Allergies

Conditions
-----------------
Food Hypersensitivity

Intervention / Treatment
-----------------
* Dietary Supplement: cow's milk
* Dietary Supplement: peanut powder


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presence or absence of specific IgE to alpha-gal or peanut Exclusion Criteria: History of severe anaphylaxis allergy to cow's milk protein

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cow's milk for alpha-gal allergics<br>daily consumption of cow's milk | Dietary Supplement: cow's milk<br>* daily consumption of cow's milk<br>|
| Experimental: Peanut powder<br>peanut oral immunotherapy | Dietary Supplement: peanut powder<br>* peanut oral immunotherapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Level of Allergen Consumed Post-oral Immunotherapy | consumption of cow's milk or peanut flour at open challenge. This is a single time-point assessment; not measured repeatedly. | Following 36 months of maintenance oral immunotherapy, participants completed an open challenge at month 37 |